



World leading stem cell research and innovation.



Corporate Overview

June 2020

This Confidential Investor Presentation (the Presentation) is being delivered to a select number of parties who have expressed an interest in pursuing a business or financial relationship with Blue Horizon International AG. Nothing contained within this Presentation alone is an offer to buy or sell securities or an offering of any product, service or fund. An offer to buy or sell securities will only be accompanied by appropriate documents including, but not limited to, a private placement memorandum or Offering Circular which will contain, among other things, a listing of possible risk factors associated with the securities being offered. All representations and warranties are hereby disclaimed. The Information contained in this presentation is intended for general Informational purposes only and is not Intended to be information sufficient for the making of a business or investment decision. While reasonable efforts have been made to ensure that the information contained in this Presentation has been obtained from sources deemed to be reliable, Blue Horizon International AG does not guaranty that the information contained herein is accurate or complete and is not responsible for any errors or omissions, or for the results obtained from the use of this information. All information in this Presentation is provided “as is” with no guarantee of completeness, accuracy, timeliness or of the results obtained from the use of this Information, and without warranty or representation of any kind, statutory, express, or implied, oral or written. In no event will Blue Horizon International AG, its related entities, or its members, partners, agents or employees be liable to you or anyone else for any decision made or action taken in reliance on the information in this Presentation alone or for any consequential, special or similar damages, even if advised of the possibility of such damages. You should conduct your own due diligence with respect to any and all information related to this document and the offering in the private placement memorandum or Offering Circular and are not entitled to rely solely on the information in this Presentation. Further, Blue Horizon International AG is under no obligation to update the material or information presented herein even if they later become aware that such information or material is no longer accurate or true. Any recipient of this Presentation assumes all risk in, and Blue Horizon International AG will not be liable for any damages arising out of, use of information including, without limitation, business decisions made or inferences drawn by anyone in reliance on the Presentation at the fact of the disclosure of the information. All communications or inquiries relating to Blue Horizon International AG should be directed to Brian Mehling at 866-263-2479 or by email to mehling@rcn.com.

Blue Horizon

International AG

was formed in 2010

to monetize stem

cell technology

and associated

regenerative

medicine.

BHI Therapeutic

Sciences was formed

in 2017 to conduct all

US business.

Blue Horizon is focused on using stem cells to treat a wide range of diseases and to provide health benefits without the use of drugs or surgery.

The company has an established manufacturing process for the necessary supply of stem cells and understands the treatment procedures via its clinical practices.

Dr. Brian Mehling is the founder of BHITS and BHIAG and is a globally recognized presence in the regenerative medicine research community. Dr. Mehling has previously founded BHI companies in Germany, Slovakia, Belize, Brazil, Jamaica, Seychelles and Israel. With BHITS, Dr. Mehling and his team are bringing their global experience to the United States. BHITS is the only Blue Horizon company licensed in the U.S. to utilize the broad swath of intellectual property created by BHIAG, as all intellectual property generated by BHIAG's overseas entities is exclusively licensed to BHITS for domestic operations.

BHITS will be conducting all United States business related to the Blue Horizon family of businesses, research and monetization of stem cell technology and associated regenerative medicine. BHITS will also be the sole conduit for the U.S. for all internationally developed Blue Horizon intellectual property. BHITS is also the sole U.S. distributor of the Alpha Blu cosmetic line, a line of products developed in Germany because of Blue Horizon's stem cell research.



Dr. Brian Mehling, MD, MS
Founder & Chief Medical Officer

Brian Mehling, M.D., M.S. is the founder and chief medical officer of Blue Horizon International (BHI). He is a practicing American orthopedic trauma surgeon, researcher, and philanthropist.

Educational Background

Dr. Mehling started his path in medicine through undergraduate study at Harvard University, obtaining his Bachelor of Arts and Master of Science degrees in Biochemistry from Ohio State University. Completing his degree of medicine at Wright State University School of Medicine, Dr. Mehling received post graduate education through residencies and fellowships at St. Joseph's Hospital in Paterson, NJ and the Graduate Hospital in Philadelphia, PA, while pursuing a Ph.D. in Chemistry.

Global Perspective

Dr. Mehling has traveled extensively throughout Asia and the Middle East observing firsthand the differences in healthcare standards. Identifying the need for a universal high quality standard, he founded Blue Horizon International.

Stem Cell Pioneer

He and his colleagues have successfully treated and monitored more than 600 patients using stem cell and regenerative therapies. Patients have been treated for a wide range of diseases and disorders including spinal cord injury and cerebral palsy.

Charitable Founder

Dr. Mehling founded the Blue Horizon Charitable Foundation, which was with the mission to assist in and finance the advancement of all aspects of stem cell therapies and cellular regenerative medicine and research in full regulatory conformance, in conjunction with the scientific community. The foundation will also support and provide charitable therapies to those suffering from degenerative diseases and debilitating conditions.



**Brian Mehling, MD, MS, Founder
Chief Medical Officer**

Internationally known, board-certified orthopedic trauma surgeon

- Operates own practice, Mehling Orthopedics, in West Islip, NY and Hackensack, NJ
- Undergone 30+ stem cell therapies himself in the last 7 years
- Harvard University undergraduate



**Doreen Santora, RN, MHA
Chief Executive Officer**

- 23 years of experience in healthcare management
- Served as Senior Vice President of Operations at Hackensack University Medical Center
- Registered nurse with a Masters of Science degree in Health Administration



**Eddie Amarante
Director of Cultural Relations**

- Guides Blue Horizon's community and stakeholder relationships
- Serves as chairman of the unaffiliated not-for-profit company, Blue Horizon Charitable Foundation



Elizabeth Mehling, JD

- Founding partner of Mehling & Associates, PC, a law practice specializing in taxation, family, office, and private client services
- Master of Laws in Taxation from New York University School of Law in 2002; her Doctor of Law (J.D.) in 2001



Brian Mehling

Founder, Chief Medical Officer, MD, MS

- Internationally known, board-certified orthopedic trauma surgeon
- Operates own practice, Mehling Orthopedics, in West Islip, NY and Hackensack, NJ
- Successfully treated and monitored 600+ subjects using stem cell therapies
- Principal Investigator of clinical studies on umbilical cord mesenchymal stem cell therapy of continued respiratory disability after acute COVID-19 infection and hospitalized subjects with severe COVID-19 pneumonia.



Doreen Santora

Chief Executive Officer, RN, MPH

- 23 years of experience in healthcare management
- Served as Senior Vice President of Operations at Hackensack University Medical Center
- Registered nurse with a Masters of Science degree in Health Administration
- Supervising clinical research activities related to umbilical cord mesenchymal stem cell therapy of continued respiratory disability after acute COVID-19 infection and hospitalized subjects with severe COVID-19 pneumonia



Dongcheng Wu

Chief Science Officer, MD, PhD

- Professor at Wuhan University School of Basic Medical Science
- Chu Tian Scholar
- Leading expert in stem cell mechanics
- Focus on designing clinical trials using stem cells to treat spinal cord injury
- Supervising clinical trials on the application of mesenchymal stem cells for the treatment of multiple medical conditions. His latest clinical research study is dedicated to umbilical cord mesenchymal stem cell therapy of pneumonia caused by 2019 novel coronavirus



Marine Manvelyan

Clinical Research Scientist, PhD

- Postdoctoral education at the Institute of Human Genetics, University Hospital Jena, Germany
- Fifteen years of experience in biomedical research, five years of experience in clinical research
- Author of over 40 research papers in peer-reviewed journals
- Developing clinical study protocols on umbilical cord mesenchymal stem cell therapy of continued respiratory disability after acute COVID-19 infection and hospitalized subjects with severe COVID-19 pneumonia



Vicky Yamamoto

Chair of the Scientific Advisory Board, PhD

- Cancer scientist at the Keck School of Medicine of USC in Los Angeles, California
- Specialized in neurodevelopment, cell signaling, cancer stem cell, pre-clinical development, and molecular targeted therapy for cancer treatment
- Overseeing and consulting on all clinical research protocols, including COVID-19 clinical studies



Eddie Amarante

Director of Cultural Relations

- Guides Blue Horizon's community and stakeholder relationships
- Serves as chairman of the unaffiliated not-for-profit company, Blue Horizon Charitable Foundation



**Katarina
Novokova**

President, BHI Slovakia

- Oversees Blue Horizon's operations in Slovakia
- Director of relations of Blue Horizon Charitable Foundation
- Nominee for the Economic World Forum's Young Global Leaders (Class of 2019)



John Pape

Chief Financial Officer

- Over 30 years of experience in accounting and finance
- Spent 16 years as a CFO



Klara Doert

President, Business Development


- Oversees Blue Horizon's Stem Cell and Skin Care business development
- 20 years of leadership experience in cosmeceuticals, spa, medical spa, and alternative therapy industries in Europe, the United States of America, and Asia.
- Director of the Global Healthcare Forum of Diplomatic Council

Scientific Advisory Board



Andre Ragnauth, Ph.D.

- Cognitive neuroscientist and entrepreneur affiliated with Harlem Biospace, the first biotechnology startup incubator in New York City
- Founding director of the biomedical accelerator facility at Mount Sinai School of Medicine, NY
- Medical Professor at the Sophie Davis Medical School



Vicky Yamamoto, Ph.D.

- Cancer scientist at the Keck School of Medicine of USC in Los Angeles, California
- Specialized in neurodevelopment, cell signaling, cancer stem cell, pre-clinical development, and molecular targeted therapy for cancer treatment
- Ph.D., Keck School of Medicine of USC; B.S., B.A., Mount Saint Mary's College



Dongcheng Wu, M.D., Ph.D.

- Professor at Wuhan University School of Basic Medical Science
- Chu Tian Scholar
- Leading expert in stem cell mechanics
- Focus on designing clinical trials using stem cells to treat spinal cord injury
- Chief Science Officer of Blue Horizon



Michael Platt, M.D.

- James S. Riepe University Professor; Department of Neuroscience
- Perelman School of Medicine; Department of Psychology, School of Arts and Sciences
- Marketing Department, The Wharton School, University of Pennsylvania



Jason DICTENBERG, Ph.D.

- CEO and Chief Scientist, AccelBio LLC
- Research Associate Professor, SUNY Downstate Medical Center
- Ph.D., Molecular Medicine, University of Massachusetts Medical School/Harvard Medical School
- B.A., Molecular Biology and Genetics, Highest Honors in Research, Brandeis University



Joseph Feldman, M.D.

- Board-certified emergency medicine physician in NY and NJ
- Current medical director at Mount Sinai Urgent Care and former chairman of the Emergency/Trauma Center at Hackensack University Medical Center
- Author of several publications and books.



Michael A. Kelly, M.D.

- Chairman, Department of Orthopaedic Surgery, Hackensack University Medical Center
- Past President, American Knee Society
- Former Team Physician, NBA's NJ Nets
- Lectures extensively throughout the US and internationally




Hansjorg Lammers, DMD, Ph.D.

- Practicing dentist lecturer, author, and developer of nutraceuticals
- Holistic dentist
- Keynote Speaker, Anti-Aging Medicine Specialization in Europe
- Head of the FirstBioDentSpa Clinic



Stephen Roman, M.D.

- Incorporates the latest advancements in Regenerative Medicine to the treatment of patients with disorders of the spine and musculoskeletal system
- Board certified in Physical Medicine & Rehabilitation and Pain Management
- Graduate of Seton Hall University and New Jersey Medical School



Kurt Kreiter, Ph.D.

- 20+ years experience with epidemiological studies and clinical trials in degenerative dementias, cerebrovascular disorders, and MS
- Senior Director of Medical Affairs at SAGE Therapeutics
- BSc Psychology, University of Houston; Ph.D. Neuropsychology, City University of New York; post-doctoral work Columbia University

Blue Horizon is working to bring the miracle of life saving stem cell treatments to the world

We address widespread medical conditions, including...



COVID-19

As of June 10, 2020, the number of both confirmed and presumptive positive cases of the COVID-19 disease reported in the United States had reached 1,973,797 with 112,133 deaths reported among these cases ⁽¹⁾



Stroke

15 million people suffer a stroke each year worldwide. In the United States, nearly 800,000 people suffer from a stroke annually, making it the leading cause of serious, long term disability in the US and the United Kingdom ⁽¹⁾



Alzheimer's Disease

An estimated 50 million people, including 5.5 million Americans, suffer from Alzheimer's and other related dementias ⁽²⁾



Diabetes

422 million people worldwide, including 29 million Americans, have diabetes, with another estimated 8.1 million Americans undiagnosed, living unaware of their condition ⁽¹⁾



Heart Disease

7.2 million people worldwide, including 610,000 Americans, die each year from heart disease ⁽¹⁾



Arthritis

54.4 million people in the U.S suffer from arthritis ⁽¹⁾

1) According to the US Centers for Disease Control and Prevention and the World Health Organization

2) According to the Alzheimer's Association and Alzheimer's Disease International

About Stem Cells and Stem Cell Methods

Stem cells have the remarkable potential to develop into many different cell types in the body. They can be used to regenerate the human body without drugs or surgery.

Origin of Stem Cells

- Treatment initiated over 50 years ago
- Originated from bone marrow transfers
- Stem cells regularly divide to repair and replace worn out or damaged tissue
- Due to legal and ethical issues of using embryonic cells, Blue Horizon uses placenta cord tissue from healthy babies – without any injury to baby or mother
- Other source of stem cells is from patients themselves

Overall advantages of stem cells

- Bring down long term medical costs
- Alleviate Suffering
- Potential to repair damage on all parts of body which have not yet been repaired
- No medication required- holistic approach

Research Studies in Regenerative Medicine

- Retrospective chart review studies of human umbilical cord blood derived mononuclear cell therapy in subjects with spinal cord injury, stroke, and chronic inflammation
- Retrospective chart review study of human adipose tissue derived mononuclear cell therapy in subjects with musculoskeletal conditions
- Safety study of allogeneic cord blood hematopoietic progenitor cell therapy of subjects with chronic inflammation (not yet initiated)

Umbilical Cord Blood (UCB)

- Rich source of hematopoietic stem cells and progenitor cells as well as non-hematopoietic stem cells
- Can be directly used after isolation without expansion
- The human leukocyte antigen type does not need a closely matched donor for non-hematopoietic purposes as these cells are less likely to induce immunological reactions

Autologous Stem Cells

- Removal of adipose tissue under local anesthesia
- Lipoaspirate after extraction
- Isolation of stromal vascular fraction with MSCs
- Preparation ready for administration
- Administration of preparation into the hip or knee joint

Wharton's Jelly (WJ)

- Expanded MSCs from WJ of healthy donors who underwent elective full-term pregnancy caesarean sections
- Umbilical Cord is collected from primiparous pregnant women receiving caesarean section in accordance with the sterile procedure guidelines in each hospital– no injury to the baby or mother

Treatment Modalities

- Intravenous infusion for peripheral injury or disease
- Intrathecal injection – for central nervous system pathology
- Intra-articular injection – for joint pathology

Many studies have shown that Mesenchymal Stem Cells have anti-inflammatory and tissue repair functions, being a great potential for the prevention and treatment of viral diseases

The clinical trial, conducted by Hospital Puren Affiliated to Wuhan University of Science and Technology and Wuhan Hamilton Biotechnology Co., Ltd (Hubei, China) is aimed to evaluate the safety and efficacy of human Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) in 48 patients with pneumonia caused by 2019 novel coronavirus. Preliminary results indicate that UC-MSC therapy is safe and effective in therapy of patients with pneumonia caused by 2019 novel coronavirus. Nine intensive care unit patients showed significant improvement with no adverse reactions.

BHI Therapeutic Sciences (BHITS) received Institutional Review Board (IRB) approval on the study conducted in Wuhan, China. The study title is “Retrospective Case Series Study of Umbilical Cord Mesenchymal Stem Cell Therapy in Previously Treated Subjects with Pneumonia Caused by 2019 Novel Coronavirus” (Protocol number: BHITS20- 2019-nCoV. IRB approval number: IRCM-2020-243).

1. Treatment of Hospitalized Subjects with Severe COVID-19 Pneumonia
2. Treatment of Continued Respiratory Disability after Acute COVID-19 Infection

The rationale for these clinical studies is the further characterization of the safety and efficacy of UC-MSCs, delivered via an intravenous route of administration, for treatment of symptomatic COVID-19 pneumonia in hospitalized patients and continued respiratory disability after acute COVID-19 Infection.

Submission of two clinical study proposals for hUC-MSCs in the Treatment of Hospitalized Subjects with Severe COVID-19 Pneumonia and Continued Respiratory Disability after Acute COVID-19 Infection:

- April 3, 2020: Submission to [medicalcountermeasures.gov](https://www.medicalcountermeasures.gov) to request the U.S. government Coronawatch Meeting (USA).
- April 8, 2020: Submission to special emergency program created by FDA – Coronavirus Treatment Acceleration Program (USA).
- May 9, 2020: Submission to the Federal Ministry of Education and Research (Germany).

In collaboration with DataRevive USA LLC, BHITS is developing Pre-IND package for hUC-MSCs treatment of COVID-19 Pneumonia. Results of our previous clinical studies and nonclinical studies will be used to support our IND application.

BHI Therapeutic Sciences is planning to apply two clinical studies on UC-MSC treatment for hospitalized subjects with severe COVID-19 pneumonia and continued respiratory disability after acute COVID-19 infection in BHITS two locations:

- Malacky Hospital (Malacky, Slovakia)
- BHITS Jamaica (The Village at Half Moon Montego Bay St. James, Jamaica Indies)

At the initial stage, the investment will support BHI in the development of the investigational new product (human umbilical cord blood and tissue stem cells). At this stage, BHI will submit and get endorsed by the FDA to treat a specific medical condition(s). After we get endorsed to apply our investigational product to treat a specific medical condition(s), BHI has an intention to submit new studies investigating the same product of stem cells for the treatment of multiple medical conditions.

- We completed the evaluation of the **long-term safety** (10 years post-therapy) of hUCB cell therapy in subjects with chronic inflammation, assessed by the adverse events questionnaire. The results of the study indicate that 29 subjects did not develop any serious adverse events related to hUCB cell therapy, and both intravenous and intrathecal administration routes are safe.
- Intravenous plus intrathecal administration of hUCB derived mononuclear cells was also evaluated in 30 subjects with **spinal cord injury**. A significantly higher proportion of subjects in the hUCB mononuclear cell therapy group showed improved function in pain and temperature sensation, lower limb muscle strength, bladder function, and gastrointestinal function compared to a conventional therapy group.
- The impact of hUCB mononuclear cell therapy on mobility and muscle strength of upper and lower extremities, and neurological function was analyzed in 97 subjects with ischemic and hemorrhagic stroke. Analysis of post-stroke symptoms before and after treatment showed improvement of upper and lower extremity mobility and muscle strength, and neurological function (ability to speak, urinary and bowel function). Upper and lower extremity muscle strength improved significantly in a group of subjects who received two or three intrathecal plus intravenous administrations.
- Intraarticular administration of adipose tissue-derived stem cells was evaluated in 350 subjects with **musculoskeletal conditions**. Significant decrease in subjects' pain sensation and improvement in subjects' mobility were observed three, six and 12 months comparing to seven days after therapy

Research results are published in “Experimental and therapeutic medicine” cited at PubMed Central, US National Library of Medicine, National Institutes of Health; “CellR4”, the official journal of The Cure Alliance; and presented at the numerous international conferences.

Stroke FDA Trial

- Have FDA approval to start Phase I trial
- Primary objective: evaluate the safety of Hematopoietic Stem Cells (HPC), Cord Blood in subjects with acute ischemic stroke
- Secondary objective: evaluate the efficacy of HPC, Cord Blood in subjects with acute ischemic stroke
- Study starts with 10 research subjects, will then attempt to get approval for more
- Obtained approval to charge cost of dose, cannot charge profit. Estimated charge will be \$5,000 per dose
- Three therapy sessions per research subject
- ClinicalTRials.gov Identifier: NCT03735277

The ability to charge subjects participating in clinical trials offsets the overall cost of obtaining FDA approval.

Follow-on trials

Knee Osteoarthritis Associated Pain Trial

- Planned trial following stroke trial
- Study starts with 10 research subjects
- Starting timeline of 3 - 6 months
- One therapy per research subject
- May be able to start receiving insurance reimbursement for procedure

Diabetes Trial

- Third priority
- Could be completed quickly
- Study starts with 10 research subjects
- Starting timeline of 3 – 6 months
- Three therapy sessions per research subject

Additional trials to follow

What is Alpha Blu?



- Cosmetic skin care line, produce in Germany
- BHI purchases Alpha Blu products from affiliated entity
- 75% gross margins
- Plan to partner with drop shipper

Research Studies in Wound Healing and Skin Rejuvenation

- Approved by the Institutional Review Board
- Safety Study of Alpha Blu Skin Care Line Application for Skin Anti-Aging (IRCM-2017-140, February 22, 2017)
- Safety Study of Post-Surgical Balm Application for Scar Reduction (IRCM-2016-107, May 25, 2016)

Alpha Blu Pricing

- Kit contains four products, costs \$100 (day, night, eye, and skin creams)
- Monthly recurring order costs \$90
- Individual bottles cost \$50 each
- Shipping costs \$25
- Discount codes are promoted

Research

- Alpha Blu Skin Care line is created with umbilical cord blood mesenchymal stem cells derived conditioned medium.
- It contains growth factors and cytokines, which have been shown to demonstrate paracrine mediated anti-inflammatory and wound healing effects.
- Studies show that our conditioned medium effectively increases the survival rate of skin cells under oxidative stress, so it helps improve users undesired skin conditions such as oxidation and aging. Conditioned medium stimulates gene expression of anti-inflammatory and regeneration-promoting chemokines and skin-specific molecules.
- Results from participants' self-assessments indicate overall improvement in skin appearance and skin feel, fine lines, wrinkles, eye lines, and skin texture.

Alpha Blu Distribution

- Product being marketed to dermatology practices
- Sold direct to consumers via www.alphabluskin.com
- Also sold on Amazon
- Promoted on social media
- Currently moving website to Shopify platform for better social media integration

(1) <https://www.marketwatch.com/press-release/stem-cells-market-size-is-projected-to-be-around-us-297-billion-by-2022-2018-06-19>

(2) <https://www.healthline.com/health/stem-cell-research>

BHI is developing clinical protocols with the intention to get them endorsed by the FDA and expand into the US Market. BHI Therapeutic Sciences was formed to capitalize on the progress made by the international business and expand into the US Market.

2020 (15 locations):

USA: New York (New York), Illinois (Chicago), Texas (Houston), Washington (Seattle), Florida (Miami, Tampa), Texas (Dallas, Arlington), Ohio (Columbus, Cleveland).

Canada: (Toronto, Montreal, Vancouver, Calgary, Ottawa).

2021 (30 locations)

USA: Georgia (Atlanta), Arizona (Phoenix, Tucson, Mesa), Texas (San Antonio, Austin, Fort Worth, El Paso), California (Los Angeles, San Diego, San Francisco, San Jose, Fresno, Sacramento, Long Beach, Oakland, Bakersfield, Anaheim, Santa Ana, Riverside).

Asia: Oman (Muscat, Salah), Saudi Arabia (Riyadh, Jeddah), United Arab Emirates (Abu Dhabi, Dubai), Kuwait (Kuwait City, Sabah as Salim), Japan (Tokyo, Yokohama).

2022 (30 locations)

USA: North Carolina (Raleigh), Pennsylvania (Philadelphia), Nebraska (Omaha), Missouri (Kansas City), Michigan (Detroit), Virginia (Virginia Beach), Minnesota (Minneapolis), Oklahoma (Tulsa), Utah (Salt Lake City), Colorado (Denver, Aurora), Tennessee (Nashville), Nevada (Las Vegas), Oregon (Portland), Hawaii (Honolulu), Massachusetts (Boston), Indiana (Indianapolis), Kentucky (Lexington), Nevada (Henderson), North Carolina (Charlotte).

European countries: The Czech Republic (Prague), Luxembourg (Luxembourg), Poland (Warsaw), Switzerland (Zurich), Spain (Madrid), Ireland (Dublin), Italy (Rome), The Netherlands (Amsterdam), Portugal (Lisbon), Monaco (Monaco).

2023 (25 locations)

European countries: Cyprus (Nicosia), Greece (Athens), Romania (Bucharest), Sweden (Stockholm), Russia (Moscow), Norway (Oslo), Belarus (Minsk), Denmark (Copenhagen), Montenegro (Podgorica), Malta (Valetta), Andorra (Andorra la Vella), Albania (Tirana), San Marino (San Marino), Estonia (Tallinn), Finland (Helsinki).

European countries: Germany (Berlin, Frankfurt, Munich, Hamburg, Cologne), France (Paris), United Kingdom (London), Austria (Vienna), Belgium (Brussels), Croatia (Zagreb).

2024 (25 locations)

Asia: Indonesia (Jakarta, Surabaya), Vietnam (Hanoi), Philippines (Manila), Hong Kong (Hong Kong), Singapore (Singapore), Cambodia (**Phnom Penh**), Iran (Tehran), Israel (Jerusalem, Tel Aviv), India (Kolkata, Chennai, Bangalore), Pakistan (Karachi), Iraq (Baghdad), Bangladesh (Dhaka), Sri Lanka (Colombo), Malaysia (Kuala Lumpur), Maldives (Malé), Bhutan (Thimphu), Nepal (Kathmandu), Uzbekistan (Tashkent), Lebanon (Beirut), Armenia (Yerevan), Kyrgyzstan (Bishkek).

2025 (25 locations)

Central and South America: Mexico (Mexico City), Belize (Belize city), Cuba (Havana), Costa Rica (San José), Dominican Republic (Santo Domingo), Puerto Rico (San Juan), Panama (Panama city), Jamaica (Kingston), The Bahamas (Nassau), Guatemala (Guatemala City), Cayman Islands (George Town), Brazil (São Paulo, Rio de Janeiro), Argentina (Buenos Aires, Córdoba), Colombia (Bogotá), Chile (Santiago), Peru (Metropolitan Lima), Venezuela (Caracas), Ecuador (Guayaquil), Australia (Sydney, Melbourne); Africa: South Africa (Capetown), Sudan (Khartoum), Egypt (Cairo).

Blue Horizon International AG	2020 (Projected)		2021 (Projected)		2022 (Projected)		2023 (Projected)		2024 (Projected)	
Revenue	\$	168,615	\$	2,316,747	\$	26,572,494	\$	103,820,258	\$	240,144,992
Costs & Expenses										
Cost of Goods Sold	\$	82,434	\$	1,132,632	\$	12,990,997	\$	50,756,571	\$	117,404,219
General & Administrative	\$	702,000	\$	2,565,281	\$	6,998,805	\$	10,939,342	\$	16,487,914
Marketing	\$	100,800	\$	702,174	\$	2,252,517	\$	4,825,442	\$	7,833,633
Depreciation & Amortization	\$	2,500	\$	60,656	\$	209,950	\$	418,561	\$	609,397
R&D	\$	63,000	\$	168,468	\$	246,654	\$	361,127	\$	528,726
Total Cost & Expenses	\$	950,734	\$	4,629,211	\$	22,698,924	\$	67,301,042	\$	142,863,888
Income from Operation	\$	(782,119)	\$	(2,312,464)	\$	3,873,570	\$	36,519,216	\$	97,281,104
Pre-tax Income	\$	(782,119)	\$	(2,312,464)	\$	3,873,570	\$	36,519,216	\$	97,281,104
Provision for Income Tax ¹	\$	-	\$	-	\$	218,116	\$	10,057,381	\$	27,070,709
Net Income	\$	(782,119)	\$	(2,312,464)	\$	3,655,454	\$	26,461,836	\$	70,210,395
EBITDA²	\$	(779,619)	\$	(2,251,808)	\$	4,083,520	\$	36,937,777	\$	97,890,502

Note: Projections (i) are dependent upon reasonably timed funding; (ii) reflect expectations at the time this presentation was prepared; and (iii) are subject to risks, uncertainties, and assumptions that may cause these projections to differ materially from actual results. Our lack of experience with large scale operations add to the uncertainties herein. We can provide no assurance that these expectations will prove to be correct, and these financial projections should not be unduly relied upon.

¹ Based on estimated corporate tax rate and customary treatment of tax-loss carryforward

² EBITDA is not generally considered GAAP accounting

BHI Therapeutic Sciences, Inc.	2020 (projected)	2021 (projected)	2022 (projected)	2023 (projected)	2024 (projected)
Revenue					
Revenue from Alpha Blue	\$ 112,500	\$ 450,439	\$ 1,055,002	\$ 1,673,582	\$ 2,450,292
Revenue from Procedures	\$ 300,000	\$ 4,425,000	\$ 18,232,500	\$ 41,338,033	\$ 87,738,930
Total Revenue	\$ 412,500	\$ 4,875,439	\$ 19,287,502	\$ 43,011,615	\$ 90,189,221
Costs & Expenses					
Cost of Goods Sold	\$ 323,208	\$ 4,495,691	\$ 17,190,750	\$ 33,035,704	\$ 60,220,208
General & Administrative	\$ 315,000	\$ 2,285,374	\$ 5,579,998	\$ 8,770,099	\$ 13,733,165
Clinical Trials	\$ 100,000	\$ 1,000,000	\$ 3,400,000	\$ 2,400,000	\$ 1,400,000
Marketing	\$ 60,000	\$ 330,000	\$ 960,000	\$ 1,710,000	\$ 2,640,000
Depreciation & Amortization	\$ 17,500	\$ 99,870	\$ 192,170	\$ 293,871	\$ 415,032
R&D	\$ 63,000	\$ 168,468	\$ 246,654	\$ 361,127	\$ 528,726
Total Cost & Expenses	\$ 878,708	\$ 8,379,403	\$ 27,569,573	\$ 46,570,800	\$ 78,937,131
Income from Operation	\$ (466,208)	\$ (3,503,964)	\$ (8,282,071)	\$ (3,559,185)	\$ 11,252,090
Pre-tax Income	\$ (466,208)	\$ (3,503,964)	\$ (8,282,071)	\$ (3,559,185)	\$ 11,252,090
Provision for Income Tax ¹	\$ -	\$ -	\$ -	\$ -	\$ -
Net Income	\$ (466,208)	\$ (3,503,964)	\$ (8,282,071)	\$ (3,559,185)	\$ 11,252,090
EBITDA²	\$ (448,708)	\$ (3,404,094)	\$ (8,089,901)	\$ (3,265,314)	\$ 11,667,123

Note: Projections (i) are dependent upon reasonably timed funding and comprehensive FDA approvals; (ii) reflect expectations at the time this presentation was prepared; and (iii) are subject to risks, uncertainties, and assumptions that may cause these projections to differ materially from actual results. Our lack of experience with large scale operations add to the uncertainties herein. We can provide no assurance that these expectations will prove to be correct, and these financial projections should not be unduly relied upon.

¹ Based on estimated corporate tax rate and customary treatment of tax-loss carryforward

² EBITDA is not generally considered GAAP accounting

Financial Projections For Additional Single Clinic

Financial Projections	Year One (Projected)	Year Two (Projected)	Year Three (Projected)	Year Four (Projected)	Year Five (Projected)
Number of Patients	100	200	400	800	1600
Gross Stem Cell Revenue	\$ 500,000	\$ 1,000,000	\$ 2,000,000	\$ 4,000,000	\$ 8,000,000
Net Profit Before Tax	\$100 Repaid to Hospital	\$ 250,000	\$ 600,000	\$ 1,400,000	\$ 3,200,000
Hospital Share Before Tax	No Effective Net Profit	\$ 104,500	\$ 250,800	\$ 585,200	\$ 1,337,600
Estimated Ancillary Services	\$ 50,000	\$ 100,000	\$ 200,000	\$ 400,000	\$ 800,000

¹Based on estimated corporate tax rate and customary treatment of tax-loss carry forward

²EBITDA is not generally considered GAAP accounting

Note: Projections are dependent upon reasonably timed funding, relate to future performance, and reflect expectations at the time this presentation was prepared. Projections are subject to risks, uncertainties, and assumptions that may cause these projections to differ materially from the actual results. We can provide no assurance that these expectations will prove to be correct and these financial projections should not be unduly relied upon.

Blue Horizon intends to provide investors with liquidity options based on an accelerated timeline in comparison to the average private investment



Blue Horizon intends to list its stock on the Nasdaq or New York Stock Exchange as soon as necessary revenue and growth metrics allow, but much earlier than companies traditionally wait before going through the IPO process



The company will opportunistically entertain buy-out offers from “big pharma” looking to add this unique technology to their therapeutic portfolio. Offers must capture the full value-potential the company believes exist for its shareholders.

CONTACT

Brian Mehling, MD

invest@bhisciences.com (631) 893-3903

Be part of the future. Bring the miracle of these life saving stem cell treatments to the world. Help us lead the world into the next frontier of medicine.

